A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma

Lee, Claire; Grigorian, Matthew; Nolan, Ryan S.; Binder, G.; Rice, Gary

doi:10.3111/13696998.2015.1130710

Cited by 19 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our mean MPR value was 0.97±0.06. This value is higher than that of 0.85 reported in 6731 American MM patients between 2011 and 2013 [10]. Our mean MPR value was 1.01, 0.97, and 0.96 for thalidomide, lenalidomide, and pomalidomide, respectively.…”

Section: Discussioncontrasting

confidence: 77%

“…Our mean MPR value was 1.01, 0.97, and 0.96 for thalidomide, lenalidomide, and pomalidomide, respectively. The authors of the American study reported a mean MPR value of 0.83, 0.85, and 0.91 for thalidomide, lenalidomide, and pomalidomide, respectively [10]. We may hypothesize that the difference is due to the fact that American data were only obtained retrospectively from pharmacy claims without analysis of treatment discontinuation for medical reasons.…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, there is little data on IMID adherence in MM patients. Only one study evaluated IMID adherence using the Medication Possession Ratio (MPR) in 6731 American MM patients between 2011 and 2013 [10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adherence to immunomodulatory drugs in patients with multiple myeloma

et al. 2019

View full text Add to dashboard Cite

Background Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are available on IMID adherence in multiple myeloma patients. The aim of our study was to evaluate IMID adherence and to compare two indirect methods to measure IMID adherence in multiple myeloma patients: a specific questionnaire and the medication possession ratio (MPR). Another aim was to explore this specific questionnaire for the assessment of IMID adherence in multiple myeloma patients. Methods All consecutive multiple myeloma patients, with at least two consecutive dispensations of thalidomide, lenalidomide or pomalidomide in our hospital were included in this prospective study. IMID adherence was measured using a specific questionnaire and the medication possession ratio. Relationship between the questionnaire scores and variables of interest was evaluated by multiple linear regression with a robust variance estimator. Findings Sixty-three patients were included in our study. The mean questionnaire score was 8.2±1.2 and the mean medication possession ratio value was 0.97±0.06. A total of 76% of patients were considered adherent according to the questionnaire ( i . e . score ≥ 8), 94% according to the medication possession ratio ( i . e . MPR ≥ 0.90), and 70% according to the questionnaire and the medication possession ratio. No statistically significant linear association was observed between the questionnaire score and any variables of interest including medication possession ratio. All Cronbach’s alpha were relatively low (range 0.0342–0.2443), showing a low correlation of the different questions with the questionnaire score. Conclusions Our study is the first prospective study evaluating IMID adherence in multiple myeloma patients in real life. The high adherence to IMIDs reported here, regardless of the drug, is encouraging considering the efficacy, toxicity and elevated cost of IMIDs. The specific questionnaire should be used with caution to evaluate IMID adherence.

show abstract

Section: Discussioncontrasting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adherence to immunomodulatory drugs in patients with multiple myeloma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However MPR constitutes an objective criteria based on accurate pharmacy records and offers information on the possession of medication PLOS ONE [39]. The rate of adherence in the present study (97% patients with MPR � 80%) was similar to recent studies [11,12,40]. Against all expectations and contrary to other populations of cancer patients [41,42], IMiDs treatment adherence does not appear a significant issue.…”

Section: Percentage Of Answerssupporting

confidence: 86%

Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects

Périchou¹,

Ranchon²,

Herledan³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Long-term multiple myeloma therapy by immunomodulatory drugs (IMiDs) raises the question of management of adverse effects. The aim of this study is to assess the impact of an educational session for patients on the acquisition of knowledge to manage hematologic and thromboembolic adverse effects of IMiDs. In this prospective single-center study, patients attended an educational session with a hospital clinical pharmacist and a nurse. The primary endpoint was the patient’s level of knowledge for the management of IMiDs adverse effects, assess with a dedicated questionnaire administered before the session then 1 and 6 months after. Assessment of knowledge was combined with self-assessment of certainty. The secondary endpoints were adherence and IMiD treatment satisfaction. 50 patients were included. Patient knowledge increased at 1 month (p<0.001) despite a loss of knowledge at 6 months (p<0.05). Six months after the educational intervention, the number of patients with skills considered satisfactory by the pharmacist and nurse increased (p<0.01). Most patients showed satisfactory adherence, with medication possession ratio ≥ 80%. The Self CARe and MEdication Toxicity (SCARMET) study highlighted the impact of multidisciplinary follow-up in multiple myeloma patients to improve knowledge of toxicity self-management.

show abstract

“…Using pharmacy claims data, another study found that the prescription costs incurred by patients did not influence their adherence to oral MM treatments. 11 Collectively, the limited available data have typically focused on adherence as an endpoint; however, the effect of adherence on subsequent humanistic and economic outcomes for patients with MM remains unexplored.…”

Section: Introductionmentioning

confidence: 99%

Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma

Gupta

Abouzaid²,

Liebert

et al. 2018

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

show abstract

A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma

Abstract: This retrospective study demonstrated that the specialty pharmacy helped patients significantly reduce their direct cost expenditures by securing funding and co-pay assistance.

Cited by 19 publications

References 11 publications

Adherence to immunomodulatory drugs in patients with multiple myeloma

Adherence to immunomodulatory drugs in patients with multiple myeloma

Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects

Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma

Contact Info

Product

Resources

About